JAMES P ALLISON to Disease Models, Animal
This is a "connection" page, showing publications JAMES P ALLISON has written about Disease Models, Animal.
Connection Strength
0.410
-
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17.
Score: 0.057
-
Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunol Res. 2015 Aug; 3(8):849-54.
Score: 0.049
-
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014 Apr 07; 211(4):715-25.
Score: 0.045
-
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6187-92.
Score: 0.040
-
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010 Mar 15; 207(3):637-50.
Score: 0.034
-
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002 Jul; 3(7):611-8.
Score: 0.020
-
The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol. 2001 Nov; Chapter 20:20.5.1-20.5.23.
Score: 0.019
-
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov. 2021 03; 11(3):614-625.
Score: 0.018
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
Score: 0.017
-
Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality. JCI Insight. 2019 10 03; 4(19).
Score: 0.017
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.014
-
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol Res. 2016 Apr; 4(4):279-88.
Score: 0.013
-
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Feb; 25(2):208-24.
Score: 0.012
-
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014 Jun 16; 25(6):719-34.
Score: 0.011
-
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43.
Score: 0.010
-
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012 Jan 15; 72(2):430-9.
Score: 0.010
-
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-?1 cytokine. Immunity. 2011 Jul 22; 35(1):123-34.
Score: 0.009
-
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 2008 Aug; 57(8):1263-70.
Score: 0.007
-
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):728-34.
Score: 0.006